

View recent presentations and learn more about upcoming events.

□

## Third quarter results 2021

October 26, 2021

Basel, Switzerland

[Watch the webcast](#)

14:00 CEST | 13:00 BST | 08:00 EDT

More upcoming events

### **November 10, 2021 - UBS European Conference**

London, UK

### **November 17, 2021 - Jefferies Healthcare Conference**

London, UK

### **November 17-18, 2021 - Wolfe Conference**

Virtual

### **November 30, 2021 - Redburn Conference**

London, UK

### **December 02, 2021 - Meet Novartis Management**

Virtual

### **December 09, 2021 - Berenberg European Conference**

London, UK

### **January 10, 2022 - J.P. Morgan Healthcare Conference**

San Francisco, USA

- [Recent Events](#)
- [2020 Archive](#)
- [2019 Archive](#)
- [2018 Archive](#)

### **ESG Investor Day**

September 30, 2021

[Watch the webcast](#)

[Download the podcast \(MP3 66 MB\)](#)

[Access our interactive slide deck \(PDF 9.6 MB\)](#)

[Read the media release](#)

[Novartis ESG Investor Day 2021 6 key takeaways](#)

### **Bernstein Strategic Decisions Conference**

September 23, 2021

### **Baader Investment Conference**

September 21, 2021

### **Bank of America Merrill Lynch Global Healthcare Virtual Conference**

September 15, 2021

### **Morgan Stanley Global Healthcare Conference**

September 13, 2021

### **Citi's GEMS Virtual Conference 2021**

September 08, 2021

### **Second quarter results 2021**

July 21, 2021

Basel, Switzerland

Media release:

[English \(PDF 0.4 MB\)](#) | [Deutsch \(PDF 0.4 MB\)](#) | [Français \(PDF 0.4 MB\)](#)

[Interim financial report \(PDF 0.5 MB\)](#)

---

[Watch the webcast](#)

[Read the presentation transcript](#)

[Download the podcast \(MP3 45 MB\)](#)

[Download the interactive presentation \(PDF 4.5 MB\)](#)

[Novartis ESG Update - July 22, 2021 \(PDF 1.8 MB\)](#)

### **Guggenheim Biopharma's Next Decade**

June 23, 2021

### **Iptacopan (LNP023) update**

June 22, 2021

[Watch the webcast](#)

[Download the podcast \(MP3 40 MB\)](#)

[Download the presentation \(PDF 2.2 MB\)](#)

### **dbAccess Conference**

June 16-17, 2021

Berlin, Germany

### **Citi European Healthcare Conference**

June 15, 2021

### **Goldman Sachs Conference**

June 09-10, 2021

### **Oncology update**

June 08, 2021

[Watch the webcast](#)

[Download the presentation \(PDF 2.5 MB\)](#)

### **Bernstein Annual Strategic Decisions**

June 04, 2021

### **Jefferies Healthcare Conference**

June 03, 2021

### **Webinar: Materiality and impact valuation as key enablers of corporate purpose**

June 01, 2021

[Register for the event](#)

### **UBS Global Healthcare Conference**

May 24, 2021

### **Berenberg Conference**

May 18, 2021

### **Cardiovascular update**

May 18, 2021

[Watch the webcast](#)

[Download the presentation \(PDF 3.6 MB\)](#)

[Download the podcast \(MP3 43 MB\)](#)

## **Bank of America ML Healthcare Conference**

May 11, 2021

### **First quarter results 2021**

April 27, 2021

Basel, Switzerland

Media release:

[English \(PDF 0.2 MB\)](#) | [Deutsch \(PDF 0.2 MB\)](#) | [Français \(PDF 0.2 MB\)](#)

[Interim financial report \(PDF 0.4 MB\)](#)

---

[Watch the webcast](#)

[Read the presentation transcript](#)

[Download the podcast \(MP3 40 MB\)](#)

[Download the interactive presentation \(PDF 7.2 MB\)](#)

[Novartis ESG Update - April 28, 2021 \(PDF 0.3 MB\)](#)

## **Guggenheim Protein Degradation Day**

March 16, 2021

## **Barclays Healthcare Conference**

March 09, 2021

## **Annual General Meeting**

March 02, 2021

Basel, Switzerland

[Visit the Annual General Meeting section](#)

## **Cowen Healthcare Conference**

March 01, 2021

## **Leerink Global Healthcare Conference**

February 25, 2021

[Watch the webcast](#)

## **Entresto® FDA Label Expansion Investor Q&A Call**

February 17, 2021  
Basel, Switzerland

[Watch the webcast](#)

[Download the podcast \(MP3 22 MB\)](#)

[Download the presentation \(PDF 0.6 MB\)](#)

### **Citi Immuno-Oncology Conference**

February 17, 2021

### **Guggenheim Healthcare Talks | Oncology Day**

February 11, 2021

### **Materiality Assessment Webinar: Dialogue matters – support us to spur positive impact**

February 08, 2021

[Watch the webcast](#)

[Download the presentation \(PDF 3.3 MB\)](#)

### **Fourth Quarter and Full Year Results 2020 and Annual Report 2020 publication**

January 26, 2021  
Basel, Switzerland

Media release:

[English \(PDF 0.2 MB\)](#) | [Deutsch \(PDF 0.2 MB\)](#) | [Français \(PDF 0.2 MB\)](#)

[Condensed financial report \(PDF 0.9 MB\)](#)

---

[Watch the webcast](#)

[Read the presentation transcript](#)

[Download the podcast \(MP3 45 MB\)](#)

[Download the presentation \(PDF 5.6 MB\)](#)

[Access our interactive slide deck \(PDF 12 MB\)](#)

[Novartis ESG Update - January 27, 2021 \(PDF 0.5 MB\)](#)

---

[Download the Annual Report 2020 \(PDF 3.5 MB\)](#)

[Visit the Novartis Annual Reporting Suite section](#)

### **J.P. Morgan Healthcare Conference**

January 11, 2021

Virtual / San Francisco, USA

[Listen to the webcast](#)

[Download the presentation \(PDF 1.0 MB\)](#)

### **Co-Creating Impact Summit**

December 09, 2020

[Register for the event](#)

[Download the agenda \(PDF 0.1 MB\)](#)

### **Meet Novartis Management**

November 24, 2020

[Download the agenda \(PDF 0.1 MB\)](#)

[Access our interactive slide deck \(PDF 98 MB\)](#)

[Read the media release](#)

[Download the podcast \(MP3 58 MB\)](#)

Watch the webcast:

[Main audience event link](#) | [Audience event link China](#)

Webcast password: novartis2020

Meet Novartis Management speakers:

[Group \(PDF 0.1 MB\)](#)

[Pipeline / R&D \(PDF 0.1 MB\)](#)

[Pharmaceuticals \(PDF 0.1 MB\)](#)

[Oncology \(PDF 0.1 MB\)](#)

[Sandoz \(PDF 0.1 MB\)](#)

### **Webinar: Measuring and evaluating social outcomes of access initiatives**

October 28, 2020

[Register for the event](#)

### **Third quarter results 2020**

October 27, 2020

Basel, Switzerland

Media release:

[English \(PDF 0.2 MB\)](#) | [Deutsch \(PDF 0.2 MB\)](#) | [Français \(PDF 0.3 MB\)](#)

[Interim financial report \(PDF 0.8 MB\)](#)

---

[Watch the webcast](#)

[Read the presentation transcript](#)

[Download the podcast \(MP3 41 MB\)](#)

[Download the presentation \(PDF 2.7 MB\)](#)

[Novartis ESG Update - October 28, 2020 \(PDF 0.5 MB\)](#)

### **Novartis ESG Investor Event**

September 01, 2020

[Download the presentation \(PDF 3.2 MB\)](#)

[Read the media release](#)

### **Kesimpta® FDA Approval Investor Call**

August 21, 2020

Basel, Switzerland

[Download the podcast \(MP3 28 MB\)](#)

[Download the presentation \(PDF 1.0 MB\)](#)

### **ESG materiality assessment webinar: Wealth and Health - Reframing healthcare costs as economic investments**

July 30, 2020

[Register for the event](#)

### **Second quarter results 2020**

July 21, 2020

Basel, Switzerland

Media release:

[English \(PDF 0.2 MB\)](#) | [Deutsch \(PDF 0.2 MB\)](#) | [Français \(PDF 0.3 MB\)](#)

[Interim financial report \(PDF 0.8 MB\)](#)

---

[Read the presentation transcript](#)

[Download the podcast \(MP3 44 MB\)](#)

[Download the presentation \(PDF 2.6 MB\)](#)

[Novartis ESG Update - July 24, 2020 \(PDF 0.6 MB\)](#)

### **ESG materiality assessment webinar: Embracing double materiality in responding to the COVID-19 pandemic**

June 25, 2020

[Register for the event](#)

### **Oncology Pipeline Update**

June 15, 2020

Basel, Switzerland

[Download the podcast \(MP3 44 MB\)](#)

[Download the presentation \(PDF 3.3 MB\)](#)

### **ESG materiality assessment webinar: sickle cell disease**

May 28, 2020

[Register for the event](#)

### **First quarter results 2020**

April 28, 2020

Basel, Switzerland

Media release:

[English \(PDF 0.2 MB\)](#) | [Deutsch \(PDF 0.2 MB\)](#) | [Français \(PDF 0.2 MB\)](#)

[Interim financial report \(PDF 0.6 MB\)](#)

---

[Read the presentation transcript](#)

[Download the podcast \(MP3 45 MB\)](#)

[Download the presentation \(PDF 3.0 MB\)](#)

[Novartis ESG Update – April 29, 2020](#)

### **Zolgensma® MDA Data Investor Call**

March 30, 2020

Basel, Switzerland

[Download the podcast \(MP3 30 MB\)](#)

[Download the presentation \(PDF 1.1 MB\)](#)



## **Annual General Meeting**

February 28, 2020

Basel, Switzerland

[Visit the Annual General Meeting section](#)

## **Fourth Quarter and Full Year Results 2019 and Annual Report 2019 publication**

January 29, 2020

Basel, Switzerland

Media release:

[English \(PDF 0.1 MB\)](#) | [Deutsch \(PDF 0.1 MB\)](#) | [Français \(PDF 0.2 MB\)](#)

[Condensed financial report \(PDF 0.6 MB\)](#)

---

[Read the presentation transcript](#)

[Download the podcast \(MP3 43 MB\)](#)

[Download the presentation \(PDF 3.6 MB\)](#)

---

[Download the Annual Report 2019 \(PDF 4 MB\)](#)

[Visit the Novartis Annual Reporting Suite section](#)

## **J.P. Morgan Healthcare Conference**

January 13, 2020

San Francisco, USA

[Read the transcript](#)

[Download the presentation podcast \(MP3 10 MB\)](#)

[Download the Q&A podcast \(MP3 12 MB\)](#)

[Download the presentation \(PDF 1.4 MB\)](#)

## **R&D Day**

December 05, 2019

London, UK

[Read the media release](#)

[Download the agenda \(PDF 0.1 MB\)](#)

[Download the presentation \(PDF 8.1 MB\)](#)

## **Novartis enters into agreement to acquire The Medicines Company**

November 25, 2019

Basel, Switzerland

[Read the media release](#)

[Read the presentation transcript](#)

[Download the podcast \(MP3 26 MB\)](#)

[Download the presentation \(PDF 0.6 MB\)](#)

### **Third quarter results 2019**

October 22, 2019

Basel, Switzerland

Media release:

[English \(PDF 0.1 MB\)](#) | [Deutsch \(PDF 0.2 MB\)](#) | [Français \(PDF 0.3 MB\)](#)

[Interim financial report \(PDF 0.8 MB\)](#)

---

[Read the presentation transcript](#)

[Download the presentation \(PDF 2.3 MB\)](#)

### **Beovu® FDA Approval**

October 08, 2019

Basel, Switzerland

[Read the media release](#)

[Download the presentation \(PDF 1.4 MB\)](#)

[Download the podcast \(MP3 22 MB\)](#)

### **Kisqali® MONALEESA-3 ESMO Data Investor Call**

October 01, 2019

Basel, Switzerland

[Download the podcast \(MP3 14 MB\)](#)

[Download the presentation \(PDF 1.8 MB\)](#)

### **Ofatumumab (OMB157) ECTRIMS Data Investor Call**

September 16, 2019

Basel, Switzerland

[Download the podcast \(MP3 26 MB\)](#)

[Download the presentation \(PDF 1.1 MB\)](#)

### **ESG Investor Event**

September 09, 2019

London, UK

[Download the podcast \(MP3 40 MB\)](#)

[Download the presentation \(PDF 4.8 MB\)](#)

## **Zolgensma® Update**

August 07, 2019

[Read the media release \(PDF 0.4 MB\)](#)

[Download the podcast \(MP3 16 MB\)](#)

## **Second quarter results 2019**

July 18, 2019

Basel, Switzerland

Media release:

[English \(PDF 0.1 MB\)](#) | [Deutsch \(PDF 0.1 MB\)](#) | [Français \(PDF 0.2 MB\)](#)

[Interim financial report \(PDF 0.6 MB\)](#)

---

[Read the presentation transcript](#)

[Download the podcast \(MP3 41 MB\)](#)

[Download the presentation \(PDF 2.2 MB\)](#)

## **ASCO Investor Event**

June 02, 2019

Chicago, USA

[Download the presentation \(PDF 0.8 MB\)](#)

## **Zolgensma® and Piqray® US FDA Approvals**

May 27, 2019

Read the media releases:

[AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy \(SMA\)](#)

[AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families](#)

[FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer](#)

[Zolgensma US prescribing information \(PDF 0.3 MB\)](#)

[Download the presentation \(PDF 0.8 MB\)](#)

[Download the podcast \(MP3 22 MB\)](#)

### **Meet Novartis Management investor event**

May 23, 2019

Boston, USA

[Read the media release](#)

[Download the presentation \(PDF 7.8 MB\)](#)

[Download the agenda \(PDF 0.1 MB\)](#)

### **Novartis enters into agreement to acquire Xiidra®**

May 09, 2019

[Read the media release](#)

[Download the podcast \(MP3 18 MB\)](#)

[Download the presentation \(PDF 0.8 MB\)](#)

### **Zolgensma AAN Data Investor Call**

May 08, 2019

Philadelphia, USA

[Download the podcast \(MP3 25 MB\)](#)

[Download the presentation \(PDF 1.0 MB\)](#)

### **First quarter results 2019**

April 24, 2019

Basel, Switzerland

Media release:

[English \(PDF 0.5 MB\)](#) | [Deutsch \(PDF 0.4 MB\)](#) | [Français \(PDF 0.8 MB\)](#)

[Interim financial report \(PDF 0.5 MB\)](#)

---

[Read the presentation transcript](#)

[Download the podcast \(MP3 41 MB\)](#)

[Download the presentation \(PDF 1.4 MB\)](#)

### **2017/2018 Results for Continuing Operations**

April 24, 2019

[Download the presentation \(PDF 0.4 MB\)](#)

### **Mayzent FDA Approval Investor Call**

March 27, 2019

Basel, Switzerland

[Read the media release](#)

[Download the presentation \(PDF 0.9 MB\)](#)

[Download the podcast \(MP3 23 MB\)](#)

### **Updated Alcon 20-F filed with the SEC**

March 22, 2019

[Download the updated Alcon 20-F \(PDF 2.0 MB\)](#)

[SEC filing](#)

### **Annual General Meeting**

February 28, 2019

Basel, Switzerland

[Visit the Annual General Meeting section](#)

### **Fourth Quarter and Full Year Results 2018 and Annual Report 2018 publication**

January 30, 2019

Basel, Switzerland

Media release:

[English \(PDF 0.1 MB\)](#) | [Deutsch \(PDF 0.1 MB\)](#) | [Français \(PDF 0.2 MB\)](#)

[Condensed financial report \(PDF 0.6 MB\)](#)

---

[Read the presentation transcript](#)

[Download the podcast \(MP3 51 MB\)](#)

[Download the presentation \(PDF 3.4 MB\)](#)

---

[Download the Annual Report 2018 \(PDF 3.8 MB\)](#)

### **J.P. Morgan Healthcare Conference**

January 07, 2019

San Francisco, USA

[Download the presentation \(PDF 1.9 MB\)](#)

December 04, 2018  
London, UK

[Download the agenda \(PDF 0.1 MB\)](#)

[Download the presentation \(PDF 5.9 MB\)](#)

### **Alcon capital markets day in New York**

November 27, 2018  
New York, USA

[Read the media release](#)

[Download the agenda \(PDF 0.1 MB\)](#)

[Download the presentation \(PDF 5.9 MB\)](#)

### **Restatement for the Innovative Medicines and Alcon Segments 2015 and 2016 following the OTC Transfer**

November 07, 2018

[Download the presentation \(PDF 0.2 MB\)](#)

### **Novartis R&D update**

November 05, 2018  
London, UK

[Read the media release](#)

[Download the agenda \(PDF 0.1 MB\)](#)

[Download the presentation \(PDF 5.6 MB\)](#)

### **ESMO Investor Call**

Oct 22, 2018

[Download the podcast \(MP3 5.1 MB\)](#)

[Download the presentation \(PDF 0.9 MB\)](#)

### **Third quarter results 2018**

Oct 18, 2018  
Basel, Switzerland

Media release:

[English \(PDF 0.1 MB\)](#) | [Deutsch \(PDF 0.1 MB\)](#) | [Français \(PDF 0.2 MB\)](#)

[Interim financial report \(PDF 0.7 MB\)](#)

[Read the presentation transcript](#)

[Download the podcast \(MP3 38 MB\)](#)

[Download the presentation \(PDF 1.8 MB\)](#)

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

---

**Source URL:** <https://www.novartis.com/investors/event-calendar>

#### List of links present in page

- <https://www.novartis.com/investors/event-calendar>
- <https://edge.media-server.com/mmc/p/x3e9pzuh>
- [#recent-events-23266](#)
- [#2020-archive-23271](#)
- [#2019-archive-23276](#)
- [#2018-archive-33901](#)
- <https://www.novartis.com/node/63001>
- <https://onlinexperiences.com/Launch/QReg/ShowUUID=31827FFF-26CE-40D7-9594-755B78163C9A&LangLocaleID=1033>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2021-09-novartis-esg-day-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2021-09-novartis-esg-day-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-09-novartis-esg-investor-day-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2021-09-novartis-esg-investor-day-presentation.pdf)
- <https://www.novartis.com/news/media-releases/novartis-accelerates-efforts-toward-esg-targets-increase-access-medicines-improve-health-equity-and-achieve-net-zero-carbon-emissions>
- <https://www.youtube.com/watch?v=1SAjEYdky5k>
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2021-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2021-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2021-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2021-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2021-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2021-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-07-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2021-07-interim-financial-report-en.pdf)
- <https://edge.media-server.com/mmc/p/t6hj2xsz>
- <https://www.novartis.com/investors/financial-data/quarterly-results/2021-q2-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-09/q2-2021-investor-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-09/q2-2021-investor-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2021-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2021-investor-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/environmental-social-and-governance-july-2021-update.pdf](https://www.novartis.com/sites/novartis_com/files/environmental-social-and-governance-july-2021-update.pdf)
- <https://onlinexperiences.com/Launch/QReg/ShowUUID=B4208415-ECFC-4F0D-8E83-3921EA57A562&LangLocaleID=1033>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-09/2021\\_iptacopan-lnp023-update-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-09/2021_iptacopan-lnp023-update-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2021\\_iptacopan-lnp023-update-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2021_iptacopan-lnp023-update-presentation.pdf)
- <https://onlinexperiences.com/Launch/QReg/ShowUUID=A07ADD67-5A5E-402A-83DF-9635E7DC9742&LangLocaleID=1033>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-06-novartis-asco-call-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2021-06-novartis-asco-call-presentation.pdf)
- <https://survey.alchemer.eu/s3/90325786/Registration-Materiality-Assessment-Webinar-1-June-2021>
- <https://edge.media-server.com/mmc/p/ikivbyzp>
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-may-2021-cardiovascular-update.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-may-2021-cardiovascular-update.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-09/novartis-cardiovascular-update.mp3](https://www.novartis.com/sites/novartis_com/files/2021-09/novartis-cardiovascular-update.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2021-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2021-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2021-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2021-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2021-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2021-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-04-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2021-04-interim-financial-report-en.pdf)
- <https://edge.media-server.com/mmc/p/8htwmdkn>
- <https://www.novartis.com/investors/financial-data/quarterly-results/2021-q1-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-09/q1-2021-investor-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-09/q1-2021-investor-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2021-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2021-investor-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/environmental-social-and-governance-apr-2021-update.pdf](https://www.novartis.com/sites/novartis_com/files/environmental-social-and-governance-apr-2021-update.pdf)
- <https://www.novartis.com/investors/shareholder-information/annual-general-meeting>
- <https://wsw.com/webcast/svbleerink47/nvs/2471936>

- <https://edge.media-server.com/mmc/p/5tu3izry>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-09/novartis-2021-entresto-label-update-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-09/novartis-2021-entresto-label-update-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-2021-entresto-label-update-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-2021-entresto-label-update-presentation.pdf)
- <http://www.kaltura.com/tiny/wjead>
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-materiality-assessment-2021-kickoff-webinar-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-materiality-assessment-2021-kickoff-webinar-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2020-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2020-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2020-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2020-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2020-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2020-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-01-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2021-01-interim-financial-report-en.pdf)
- <https://edge.media-server.com/mmc/p/g655yyy5>
- <https://www.novartis.com/investors/financial-data/quarterly-results/2020-q4-and-full-year-results-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-07/q4-2020-investor-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-07/q4-2020-investor-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2020-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2020-investor-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2020-investor-interactive-deck.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2020-investor-interactive-deck.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/environmental-social-and-governance-january-2021-update.pdf](https://www.novartis.com/sites/novartis_com/files/environmental-social-and-governance-january-2021-update.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-annual-report-2020.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-annual-report-2020.pdf)
- <https://www.novartis.com/investors/novartis-annual-reporting-suite>
- [https://jpmorgan.metameetings.net/events/healthcare21/sessions/35412-novartis/webcast?gpu\\_only=true&kiosk=true](https://jpmorgan.metameetings.net/events/healthcare21/sessions/35412-novartis/webcast?gpu_only=true&kiosk=true)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-novartis-vas-narasimhan-jpmorgan-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2021-novartis-vas-narasimhan-jpmorgan-presentation.pdf)
- <https://www.novartis.com/node/63001/printable/print>
- <https://www.novartis.com/node/63001/printable/pdf>
- <https://www.novartis.com/node/63016>
- <https://www.surveygizmo.eu/s3/90283352/Registration-CCI-Summit-Dec9>
- [https://www.novartis.com/sites/novartis\\_com/files/agenda-co-creating-impact-summit-dec-9.pdf](https://www.novartis.com/sites/novartis_com/files/agenda-co-creating-impact-summit-dec-9.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/meet-novartis-management-2020-agenda.pdf](https://www.novartis.com/sites/novartis_com/files/meet-novartis-management-2020-agenda.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/meet-novartis-management-2020-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/meet-novartis-management-2020-presentation.pdf)
- <https://www.novartis.com/news/media-releases/novartis-highlights-confidence-growing-sales-margin-expansion-fueled-market-brands-and-rich-pipeline-annual-meet-management-investor-event>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/meet-novartis-management-2020-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/meet-novartis-management-2020-presentation.mp3)
- [https://novartis.webcasts.com/starthere.jsp?ei=1386095&tp\\_key=22b40d0c7c](https://novartis.webcasts.com/starthere.jsp?ei=1386095&tp_key=22b40d0c7c)
- [https://novartis.gmwebcasts.cn/starthere.jsp?ei=1386095&tp\\_key=22b40d0c7c](https://novartis.gmwebcasts.cn/starthere.jsp?ei=1386095&tp_key=22b40d0c7c)
- [https://www.novartis.com/sites/novartis\\_com/files/meet-novartis-management-2020-group.pdf](https://www.novartis.com/sites/novartis_com/files/meet-novartis-management-2020-group.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/meet-novartis-management-2020-pipeline.pdf](https://www.novartis.com/sites/novartis_com/files/meet-novartis-management-2020-pipeline.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/meet-novartis-management-2020-pharmaceuticals.pdf](https://www.novartis.com/sites/novartis_com/files/meet-novartis-management-2020-pharmaceuticals.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/meet-novartis-management-2020-oncology.pdf](https://www.novartis.com/sites/novartis_com/files/meet-novartis-management-2020-oncology.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/meet-novartis-management-2020-sandoz.pdf](https://www.novartis.com/sites/novartis_com/files/meet-novartis-management-2020-sandoz.pdf)
- <https://www.surveygizmo.eu/s3/90277055/Registration-MA-Webinar-Measuring-and-Evaluating-Social-Outcomes-of-Access-Initiatives>
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2020-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2020-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2020-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2020-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2020-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2020-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2020-10-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2020-10-interim-financial-report-en.pdf)
- <https://edge.media-server.com/mmc/p/3soac2di>
- <https://www.novartis.com/investors/financial-data/quarterly-results/2020-q3-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/q3-2020-investor-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/q3-2020-investor-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2020-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2020-investor-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/environmental-social-and-governance-october-2020-update.pdf](https://www.novartis.com/sites/novartis_com/files/environmental-social-and-governance-october-2020-update.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2020-09-novartis-esg-day-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2020-09-novartis-esg-day-presentation.pdf)
- <https://www.novartis.com/news/media-releases/novartis-announces-ambitious-esg-targets-increase-access-medicines-and-achieve-full-carbon-neutrality>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2020-08-kesimpta-us-approval-investor-call-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2020-08-kesimpta-us-approval-investor-call-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2020-08-kesimpta-us-approval-investor-call-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2020-08-kesimpta-us-approval-investor-call-presentation.pdf)
- <https://www.surveygizmo.eu/s3/90251566/Registration-MA-Webinar-Health-is-Wealth>
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2020-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2020-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2020-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2020-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2020-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2020-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2020-07-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2020-07-interim-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2020-q2-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/q2-2020-investor-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/q2-2020-investor-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2020-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2020-investor-presentation.pdf)



- [https://www.novartis.com/sites/novartis\\_com/files/environmental-social-and-governance-july-2020-update.pdf](https://www.novartis.com/sites/novartis_com/files/environmental-social-and-governance-july-2020-update.pdf)
- <https://www.surveygizmo.eu/s3/90244617/Registration-MA-Webinar-Embracing-double-materiality>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2020-06-novartis-oncology-pipeline-update-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2020-06-novartis-oncology-pipeline-update-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2020-06-novartis-oncology-pipeline-update-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2020-06-novartis-oncology-pipeline-update-presentation.pdf)
- <https://www.surveygizmo.eu/s3/90236163/Registration-MA-Webinar-Rethinking-Healthcare-System-Strengthening>
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2020-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2020-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2020-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2020-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2020-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2020-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2020-04-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2020-04-interim-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2020-q1-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-09/q1-2020-investor-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-09/q1-2020-investor-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2020-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2020-investor-presentation.pdf)
- <https://www.novartis.com/esg/novartis-esg-update-april-29-2020>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2020-03-avexis-investor-call-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2020-03-avexis-investor-call-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2020-03-avexis-investor-call-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2020-03-avexis-investor-call-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2019-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2019-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2019-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2019-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2019-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2019-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2020-01-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2020-01-interim-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2019-q4-and-full-year-results-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/q4-2019-investor-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/q4-2019-investor-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2019-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2019-investor-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-annual-report-2019.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-annual-report-2019.pdf)
- <https://www.novartis.com/investors/event-calendar/jp-morgan-healthcare-conference-presentation-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2020-novartis-vas-narasimhan-jpmorgan-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2020-novartis-vas-narasimhan-jpmorgan-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2020-novartis-vas-narasimhan-jpmorgan-q-a.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2020-novartis-vas-narasimhan-jpmorgan-q-a.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2020-novartis-vas-narasimhan-jpmorgan-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2020-novartis-vas-narasimhan-jpmorgan-presentation.pdf)
- <https://www.novartis.com/node/63016/printable/print>
- <https://www.novartis.com/node/63016/printable/pdf>
- <https://www.novartis.com/node/63011>
- <https://www.novartis.com/news/media-releases/novartis-expects-sustain-long-term-growth-robust-pipeline-25-potential-blockbusters-highlighted-rd-day>
- [https://www.novartis.com/sites/novartis\\_com/files/2019-r-d-day-investor-agenda.pdf](https://www.novartis.com/sites/novartis_com/files/2019-r-d-day-investor-agenda.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf)
- <https://www.novartis.com/news/media-releases/novartis-acquire-medicines-company-usd-97-bn-adding-inclisiran-potentially-transformational-investigational-cholesterol-lowering-therapy-address-leading-global-cause-death>
- <https://www.novartis.com/investors/event-calendar/novartis-enters-agreement-acquire-medicines-company>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-09/novartis-agreement-acquire-medicines-company-investor-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-09/novartis-agreement-acquire-medicines-company-investor-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-agreement-acquire-medicines-company-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-agreement-acquire-medicines-company-investor-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2019-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2019-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2019-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2019-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2019-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2019-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-10-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2019-10-interim-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2019-q3-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2019-ir-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2019-ir-presentation.pdf)
- <https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept>
- [https://www.novartis.com/sites/novartis\\_com/files/2019-10-novartis-beovu-fda-approval-investor-call-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-10-novartis-beovu-fda-approval-investor-call-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-10-novartis-beovu-fda-approval-investor-call-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-10-novartis-beovu-fda-approval-investor-call-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-10-novartis-esmo-investor-call-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-10-novartis-esmo-investor-call-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-10-novartis-esmo-investor-call-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-10-novartis-esmo-investor-call-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-09-novartis-ectrims-investor-call-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-09-novartis-ectrims-investor-call-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-09-novartis-ectrims-investor-call-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-09-novartis-ectrims-investor-call-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-09-esg-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-09-esg-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-09-esg-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-09-esg-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/zolgensma-update-media-release-august-2019.pdf](https://www.novartis.com/sites/novartis_com/files/zolgensma-update-media-release-august-2019.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/zolgensma-update-recording.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/zolgensma-update-recording.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2019-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2019-media-release-en.pdf)

- [https://www.novartis.com/sites/novartis\\_com/files/q2-2019-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2019-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2019-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2019-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-07-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2019-07-interim-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2019-q2-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/q2-2019-ir-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/q2-2019-ir-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q2-2019-ir-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q2-2019-ir-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-06-novartis-asco-investor-event-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-06-novartis-asco-investor-event-presentation.pdf)
- <https://www.novartis.com/news/media-releases/avexis-receives-fda-approval-zolgensma-first-and-only-gene-therapy-pediatric-patients-spinal-muscular-atrophy-sma>
- <https://www.novartis.com/news/media-releases/avexis-announces-innovative-zolgensma-gene-therapy-access-programs-us-payers-and-families>
- <https://www.novartis.com/news/media-releases/fda-approves-novartis-piqray-first-and-only-treatment-specifically-patients-pik3ca-mutation-hrher2-advanced-breast-cancer>
- <https://www.novartis.us/sites/www.novartis.us/files/zolgensma.pdf>
- [https://www.novartis.com/sites/novartis\\_com/files/2019-05-novartis-presentation-zolgensma-piqray-fda-approval.pdf](https://www.novartis.com/sites/novartis_com/files/2019-05-novartis-presentation-zolgensma-piqray-fda-approval.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-05-novartis-presentation-zolgensma-piqray-fda-approval.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-05-novartis-presentation-zolgensma-piqray-fda-approval.mp3)
- <https://www.novartis.com/news/media-releases/novartis-highlights-company-transformation-catalyst-rich-pipeline-and-strong-progress-strategy-meet-novartis-management-investor-event>
- [https://www.novartis.com/sites/novartis\\_com/files/2019-05-meet-novartis-management-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-05-meet-novartis-management-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-05-meet-the-management-agenda.pdf](https://www.novartis.com/sites/novartis_com/files/2019-05-meet-the-management-agenda.pdf)
- <https://www.novartis.com/news/media-releases/novartis-acquire-xiidra-expanding-front-eye-portfolio-and-strengthening-leadership-eye-care>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-05-novartis-xiidra-ir-call-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-05-novartis-xiidra-ir-call-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-05-novartis-xiidra-ir-call-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-05-novartis-xiidra-ir-call-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2019-05-novartis-avexis-aan-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2019-05-novartis-avexis-aan-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-05-novartis-avexis-aan-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-05-novartis-avexis-aan-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2019-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2019-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2019-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2019-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2019-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2019-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-04-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2019-04-interim-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2019-q1-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-09/q1-2019-ir-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-09/q1-2019-ir-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q1-2019-ir-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q1-2019-ir-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-2017-2018-results-continuing-operations.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-2017-2018-results-continuing-operations.pdf)
- <https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease>
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-mayzent-fda-approval-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-mayzent-fda-approval-investor-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/novartis-mayzent-fda-approval-investor-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/novartis-mayzent-fda-approval-investor-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/alcon-20f-filing-2019.pdf](https://www.novartis.com/sites/novartis_com/files/alcon-20f-filing-2019.pdf)
- <https://www.sec.gov/Archives/edgar/data/1167379/000104746919001507/0001047469-19-001507-index.htm>
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2018-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2018-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2018-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2018-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2018-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2018-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-01-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2019-01-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2018-q4-and-full-year-results-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-08/q4-2018-ir-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-08/q4-2018-ir-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q4-2018-ir-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q4-2018-ir-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-annual-report-2018-en.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-annual-report-2018-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2019-novartis-jpmorgan-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2019-novartis-jpmorgan-presentation.pdf)
- <https://www.novartis.com/node/63011/printable/print>
- <https://www.novartis.com/node/63011/printable/pdf>
- <https://www.novartis.com/node/63006>
- [https://www.novartis.com/sites/novartis\\_com/files/2018-investors-alcon-cmd-agenda.pdf](https://www.novartis.com/sites/novartis_com/files/2018-investors-alcon-cmd-agenda.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2018-investors-alcon-cmd-presentation-dec4.pdf](https://www.novartis.com/sites/novartis_com/files/2018-investors-alcon-cmd-presentation-dec4.pdf)
- <https://www.novartis.com/news/media-releases/alcon-highlight-its-vision-strategy-and-benefits-standalone-company-investors-and-analysts-new-york-and-london>
- [https://www.novartis.com/sites/novartis\\_com/files/2018-investors-alcon-cmd-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2018-investors-alcon-cmd-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/novartis-financials-2015-2016-updated-segment-reporting.pdf](https://www.novartis.com/sites/novartis_com/files/novartis-financials-2015-2016-updated-segment-reporting.pdf)
- <https://www.novartis.com/news/media-releases/novartis-rd-update-highlights-industry-leading-development-pipeline-including-potential-blockbusters-and-advanced-therapy-platforms>
- [https://www.novartis.com/sites/novartis\\_com/files/2018-10-19-1-day-investor-agenda.pdf](https://www.novartis.com/sites/novartis_com/files/2018-10-19-1-day-investor-agenda.pdf)

- [https://www.novartis.com/sites/novartis\\_com/files/2018-11-05-r-d-day-investor-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2018-11-05-r-d-day-investor-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/2018-novartis-esmo-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/2018-novartis-esmo-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/2018-novartis-esmo-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/2018-novartis-esmo-presentation.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2018-media-release-en.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2018-media-release-en.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2018-media-release-de.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2018-media-release-de.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2018-media-release-fr.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2018-media-release-fr.pdf)
- [https://www.novartis.com/sites/novartis\\_com/files/2018-10-interim-financial-report-en.pdf](https://www.novartis.com/sites/novartis_com/files/2018-10-interim-financial-report-en.pdf)
- <https://www.novartis.com/investors/financial-data/quarterly-results/2018-q3-transcript>
- [https://www.novartis.com/sites/novartis\\_com/files/2021-10/q3-2018-ir-presentation.mp3](https://www.novartis.com/sites/novartis_com/files/2021-10/q3-2018-ir-presentation.mp3)
- [https://www.novartis.com/sites/novartis\\_com/files/q3-2018-ir-presentation.pdf](https://www.novartis.com/sites/novartis_com/files/q3-2018-ir-presentation.pdf)
- <https://www.novartis.com/node/63006/printable/print>
- <https://www.novartis.com/node/63006/printable/pdf>